Edwards Lifesciences (NYSE:EW) Raised to Buy at TD Cowen

Edwards Lifesciences (NYSE:EW) was upgraded by research analysts at TD Cowen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Marketbeat reports. The firm presently has a $97.00 price objective on the medical research company’s stock, up from their prior price objective of $90.00. TD Cowen’s price objective suggests a potential upside of 13.93% from the stock’s previous close.

EW has been the topic of several other research reports. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research note on Monday, November 3rd. Wall Street Zen downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday, September 29th. Robert W. Baird set a $87.00 price target on shares of Edwards Lifesciences and gave the company a “neutral” rating in a research report on Tuesday, December 16th. Finally, Barclays reiterated an “overweight” rating and issued a $103.00 price objective (up previously from $99.00) on shares of Edwards Lifesciences in a research report on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

Edwards Lifesciences Price Performance

NYSE:EW opened at $85.14 on Friday. The firm’s fifty day moving average is $85.06 and its two-hundred day moving average is $80.35. The firm has a market cap of $49.41 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 3.46 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the business posted $0.67 EPS. The company’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Research analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the sale, the vice president directly owned 31,870 shares in the company, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 57,824 shares of company stock valued at $4,863,323 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Level Four Advisory Services LLC increased its holdings in shares of Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 119 shares during the last quarter. Colonial Trust Co SC grew its holdings in Edwards Lifesciences by 0.4% in the 3rd quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock valued at $2,504,000 after buying an additional 120 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after acquiring an additional 130 shares during the last quarter. Prosperity Consulting Group LLC raised its holdings in shares of Edwards Lifesciences by 3.2% during the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares during the period. Finally, Howard Capital Management Inc. raised its holdings in shares of Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after acquiring an additional 132 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.